http://pulmonary-health.com Valuable Information On Pulmonary Health For You To Battle COPD, Emphyzema and Other Pulmonary Diseases Sat, 19 May 2012 09:03:14 +0000 en hourly 1 http://wordpress.org/?v=3.1 http://pulmonary-health.com/data-from-almirall-forest-labs-aclidinium-studies-on-copd-to-be-presented-at-news-medical-net/ http://pulmonary-health.com/data-from-almirall-forest-labs-aclidinium-studies-on-copd-to-be-presented-at-news-medical-net/#comments Sat, 19 May 2012 09:03:14 +0000 COPD - Google News

Data from Almirall, Forest Labs' aclidinium studies on COPD to be presented at ...
News-Medical.net
Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ...

and more »

]]>

Data from Almirall, Forest Labs' aclidinium studies on COPD to be presented at ...
News-Medical.net
Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ...

and more »

]]> http://pulmonary-health.com/data-from-almirall-forest-labs-aclidinium-studies-on-copd-to-be-presented-at-news-medical-net/feed/ 0 http://pulmonary-health.com/emphysema-medlineplus-national-library-of-medicine-national/ http://pulmonary-health.com/emphysema-medlineplus-national-library-of-medicine-national/#comments Fri, 18 May 2012 19:32:00 +0000 Bing: emphysema http://pulmonary-health.com/emphysema-medlineplus-national-library-of-medicine-national/feed/ 0 http://pulmonary-health.com/phase-2-results-for-ep-101-positive-drug-discovery-development/ http://pulmonary-health.com/phase-2-results-for-ep-101-positive-drug-discovery-development/#comments Fri, 18 May 2012 15:14:51 +0000 COPD - Google News

Phase 2 Results for EP-101 Positive
Drug Discovery & Development
Patients with moderate to severe COPD treated with EP-101 after seven days had a clinically meaningful and statistically significant improvement in lung function versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, ...

and more »

]]>

Phase 2 Results for EP-101 Positive
Drug Discovery & Development
Patients with moderate to severe COPD treated with EP-101 after seven days had a clinically meaningful and statistically significant improvement in lung function versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, ...

and more »

]]> http://pulmonary-health.com/phase-2-results-for-ep-101-positive-drug-discovery-development/feed/ 0 http://pulmonary-health.com/symptoms-of-emphysema-signs-of-emphysema-lung-cancer-2/ http://pulmonary-health.com/symptoms-of-emphysema-signs-of-emphysema-lung-cancer-2/#comments Fri, 18 May 2012 13:06:00 +0000 Bing: emphysema http://pulmonary-health.com/symptoms-of-emphysema-signs-of-emphysema-lung-cancer-2/feed/ 0 http://pulmonary-health.com/emphysema-definition-of-emphysema-in-the-medical-dictionary-by/ http://pulmonary-health.com/emphysema-definition-of-emphysema-in-the-medical-dictionary-by/#comments Fri, 18 May 2012 11:54:00 +0000 Bing: emphysema http://pulmonary-health.com/emphysema-definition-of-emphysema-in-the-medical-dictionary-by/feed/ 0 http://pulmonary-health.com/chronic-obstructive-pulmonary-disease-pubmed-health/ http://pulmonary-health.com/chronic-obstructive-pulmonary-disease-pubmed-health/#comments Fri, 18 May 2012 10:43:00 +0000 Bing: emphysema http://pulmonary-health.com/chronic-obstructive-pulmonary-disease-pubmed-health/feed/ 0 http://pulmonary-health.com/forest-and-almirall-to-present-aclidinium-bromide-clinical-data-at-the-marketwatch-press-release/ http://pulmonary-health.com/forest-and-almirall-to-present-aclidinium-bromide-clinical-data-at-the-marketwatch-press-release/#comments Fri, 18 May 2012 10:01:00 +0000 COPD - Google News

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ...
MarketWatch (press release)
Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ...

and more »

]]>

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ...
MarketWatch (press release)
Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ...

and more »

]]> http://pulmonary-health.com/forest-and-almirall-to-present-aclidinium-bromide-clinical-data-at-the-marketwatch-press-release/feed/ 0 http://pulmonary-health.com/emphysema-symptoms-causes-and-treatment-by-emedicinehealth-com/ http://pulmonary-health.com/emphysema-symptoms-causes-and-treatment-by-emedicinehealth-com/#comments Fri, 18 May 2012 09:17:00 +0000 Bing: emphysema http://pulmonary-health.com/emphysema-symptoms-causes-and-treatment-by-emedicinehealth-com/feed/ 23 http://pulmonary-health.com/novartis-to-present-positive-phase-iii-glow2-study-data-at-2012-ats-conference-pharmabiz-com/ http://pulmonary-health.com/novartis-to-present-positive-phase-iii-glow2-study-data-at-2012-ats-conference-pharmabiz-com/#comments Fri, 18 May 2012 04:33:54 +0000 COPD - Google News

Novartis to present positive phase III GLOW2 study data at 2012 ATS conference
pharmabiz.com
“The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life,” said Tim Wright, Head of Development, Novartis Pharmaceuticals. “Novartis is committed to addressing the unmet ...
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ...PharmiWeb.com (press release)
Novartis-Vectura COPD boostBusiness Weekly
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...PR Newswire (press release)

all 7 news articles »

]]>

Novartis to present positive phase III GLOW2 study data at 2012 ATS conference
pharmabiz.com
“The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life,” said Tim Wright, Head of Development, Novartis Pharmaceuticals. “Novartis is committed to addressing the unmet ...
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ...PharmiWeb.com (press release)
Novartis-Vectura COPD boostBusiness Weekly
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...PR Newswire (press release)

all 7 news articles »

]]> http://pulmonary-health.com/novartis-to-present-positive-phase-iii-glow2-study-data-at-2012-ats-conference-pharmabiz-com/feed/ 0 http://pulmonary-health.com/emphysema-wikipedia-the-free-encyclopedia/ http://pulmonary-health.com/emphysema-wikipedia-the-free-encyclopedia/#comments Fri, 18 May 2012 04:02:00 +0000 Bing: emphysema http://pulmonary-health.com/emphysema-wikipedia-the-free-encyclopedia/feed/ 1